Chronic lymphocytic leukemia (CLL) is a blood and bone marrow cancer characterized by overproduction and accumulation of abnormal B lymphocytes. It is typically indolent at onset but can progress over time and is the most common leukemia subtype in Western countries.
FDA approves Genentech's Tecentriq as first ctDNA-guided adjuvant therapy for muscle-invasive bladder cancer, and Venclexta plus acalabrutinib as first all-oral fixed-duration regimen for CLL.
Experts discuss balancing efficacy and safety in BTK inhibitor plus venetoclax combination therapy for CLL, including BTK lead-in strategies to reduce tumor lysis syndrome risk and the benefits of all-oral fixed-duration regimens.
The phase 3 AMPLIFY trial in frontline chronic lymphocytic leukemia showed improved efficacy with acalabrutinib plus venetoclax versus standard of care. The source text identified the study as NCT03836261.
AbbVie reported Q4 earnings that beat consensus estimates with $16.62 billion in revenue, while facing competitive setbacks in psoriatic arthritis and Medicare pricing challenges for Botox.
New market reports forecast significant expansion in CAR T-cell therapy, US pharmaceutical drug delivery, and healthcare nanotechnology sectors, driven by chronic disease prevalence and technological advances.
Recent studies demonstrate zanubrutinib delivers higher response rates, longer treatment persistence, and lower healthcare costs compared to acalabrutinib and ibrutinib across multiple B-cell malignancies, with particularly strong benefits in high-risk populations.
The FDA approved the combination of acalabrutinib and venetoclax as the first all-oral, fixed-duration regimen for adults with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma, based on Phase 3 AMPLIFY trial results.
Patients with p53 aberrant or 17p deleted chronic lymphocytic leukemia face a more aggressive disease course requiring specialized treatment approaches including clinical trial enrollment and referral to high-volume centers.
The FDA approved acalabrutinib plus venetoclax as the first all-oral, fixed-duration BTK inhibitor regimen for CLL/SLL and cleared monthly dosing for amivantamab in EGFR-mutated NSCLC. Additional regulatory reviews are underway for PCNSL and breast cancer treatments.
FDA approves AstraZeneca's Calquence plus venetoclax as first all-oral, 14-month fixed-duration regimen for first-line chronic lymphocytic leukemia, with 77% of patients progression-free at three years in Phase III trial.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07342478 |
ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL |
RECRUITING | PHASE3 |
| NCT07259070 |
Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma |
RECRUITING | PHASE1/PHASE2 |
| NCT07120633 |
Anti CD19 CAR-T Combined With BTKi to Treat Newly Diagnosed High-risk CLL/SLL |
RECRUITING | NA |
| NCT07108998 |
Study of Epcoritamab as a Consolidation Therapy in CLL/SLL |
RECRUITING | PHASE2 |
| NCT07108868 |
A Phase I Dose Finding Study of MB-CART2219.1 |
RECRUITING | PHASE1 |
| NCT06944119 |
Assesment of the Immune Response to RSV Vaccine in Patients With Myeloma, Lymphoma and Hematological Leukemia |
ACTIVE_NOT_RECRUITING | |
| NCT06846671 |
A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors |
RECRUITING | PHASE3 |
| NCT06767891 |
Real-world Study of Acalabrutinib |
ENROLLING_BY_INVITATION | |
| NCT06697184 |
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers. |
ACTIVE_NOT_RECRUITING | PHASE1/PHASE2 |
| NCT06557304 |
The Real World Study of BTK Inhibitor in the Treatment of Chronic Lymphocytic Leukemia in China |
NOT_YET_RECRUITING |
